当前位置: 首页 > 期刊 > 《中国现代医生》 > 2017年第34期
编号:13208144
三阴性乳腺癌新辅助化疗后淋巴结阴性原发灶癌残留的影响因素分析(4)
http://www.100md.com 2017年12月5日 中国现代医生 2017年第34期
     [10]Diaz-Botero,Espinosa Bravo S,Goncalves M,et al.Different prognostic implications of residual disease after neoadjuvant treatment:Impact of Ki67 and site of response[J].Ann Surg Oncol,2016,23(12):3831-3837.

    [11]Kim KI,Kyung Hee Lee,Tae Ryung Kim,et al. Ki67 as a predictor of response to neoadjuvant chemotherapy in breast cancer patients[J].J Breast Cancer,2014,1(1):40-46.

    [12]Wu J, Li S,Jia W,et al.Response and prognosis of taxanes and anthracyclines neoadjuvant chemotherapy in patients with triple-negative breast cancer[J].J Cancer Res Clin Oncol,2011,137(10):1505-1510.

    [13]Song YJ,Shin SH,Cho JS,et al.The role of lymphovascular invasion as a prognostic factor in patients with lymph node positive[J]. J Breast Cancer,2011,14(3):198-200.

    [14]Aristei C,Leonardi C,Straeci F,et al.Risk factors for relapse after conservative treatment in T1-T2 breast cancer with one to three positive axillary nodes:Results of an observational study[J].Ann Oncol,2011,22(4):842-847.

    [15]Yates L,Kirby S,Criehton S,et al.Risk factors for regional nodal relapse in breast cancer patients with one to three positive axillary nodes[J]. Int J Radiat Oncol Biol Phys,2012,82(5):2093-2103.

    (收稿日期:2017-08-30), http://www.100md.com(韩忠华 林舜国 许春森 韩晖)
上一页1 2 3 4